TY  - JOUR
AU  - Swami, Umang
AU  - Monga, Varun
AU  - Milhem, Mohammed
PY  - 2017
TI  - Gastrointestinal stromal tumors—are we stuck and the way forward
JF  - Translational Gastroenterology and Hepatology; Vol 2 (November 2017): Translational Gastroenterology and Hepatology
Y2  - 2017
KW  - 
N2  - Casali et al. recently published the much-awaited long-term results of the Euro-Australasian phase III randomized trial comparing standard dose of 400 mg imatinib daily with a higher dose of 400 mg twice daily in patients with advanced or metastatic gastrointestinal stromal tumors (GIST) (1). In summary, the study indicated that there is a small subset of patients who are long-term survivors and that a lower tumor burden might predict better survival (1). These results can serve as a guiding torch towards future research to improve our present understanding and management of GIST.
UR  - https://tgh.amegroups.org/article/view/3963